Free Trial
→ Another gold high? Here’s the move Wall Street is missing … (From Weiss Ratings) (Ad)tc pixel Free TAK Stock Alerts

Takeda Pharmaceutical (TAK) Stock Forecast & Price Target

Takeda Pharmaceutical logo
$15.11 -0.23 (-1.50%)
Closing price 09/12/2025 03:59 PM Eastern
Extended Trading
$15.21 +0.10 (+0.66%)
As of 09/12/2025 05:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare

Takeda Pharmaceutical - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Hold
Based on 2 Analyst Ratings
Sell
1
Hold
0
Buy
1

Based on 2 Wall Street analysts who have issued ratings for Takeda Pharmaceutical in the last 12 months, the stock has a consensus rating of "Hold." Out of the 2 analysts, 1 has given a sell rating, and 1 has given a buy rating for TAK.

Consensus Price Target

N/A

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for TAK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Takeda Pharmaceutical and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TAK Analyst Ratings Over Time

TypeCurrent Forecast
9/14/24 to 9/14/25		1 Month Ago
8/15/24 to 8/15/25		3 Months Ago
6/16/24 to 6/16/25		1 Year Ago
9/15/23 to 9/14/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
 N/A
Buy
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
 N/A
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
 N/A
Sell
1 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
 N/A
Consensus Price TargetN/AN/AN/AN/A
Forecasted UpsideN/AN/AN/AN/A
Consensus RatingHoldBuyBuyN/A

TAK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

TAK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Takeda Pharmaceutical Stock vs. The Competition

TypeTakeda PharmaceuticalMedical CompaniesS&P 500
Consensus Rating Score
2.00
2.78
2.53
Consensus RatingHoldModerate BuyModerate Buy
Predicted UpsideN/A17,489.59% Upside10.72% Upside
News Sentiment Rating
Positive News

See Recent TAK News
Positive News
Positive News
Export to Excel
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside		Details
8/21/2025Zacks Research
0 of 5 stars		 DowngradeHold ➝ Strong Sell
4/2/2025Morgan Stanley
3 of 5 stars		 UpgradeEqual Weight ➝ Overweight

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 05:56 AM ET.


Should I Buy Takeda Pharmaceutical Stock? TAK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, September 10, 2025. Please send any questions or comments about these Takeda Pharmaceutical pros and cons to contact@marketbeat.com.

Takeda Pharmaceutical
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Takeda Pharmaceutical Company Limited:

  • The current stock price is approximately $15.45, reflecting a recent upward trend, which may indicate positive market sentiment towards the company.
  • Takeda Pharmaceutical Company Limited reported earnings per share of $0.52, exceeding analysts' expectations, which suggests strong financial performance and potential for future growth.
  • The company has a market capitalization of around $49 billion, indicating it is a significant player in the pharmaceutical industry, which can provide stability and investor confidence.
  • Recent institutional investments, such as Boston Partners increasing their stake by over 91%, demonstrate growing confidence from large investors in the company's future prospects.
  • Takeda has a relatively low debt-to-equity ratio of 0.60, suggesting that the company is managing its debt levels effectively, which can be a positive indicator for financial health.

Takeda Pharmaceutical
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Takeda Pharmaceutical Company Limited for these reasons:

  • The company has a net margin of only 3.20%, which may indicate challenges in profitability compared to competitors in the pharmaceutical sector.
  • Takeda's revenue for the latest quarter was $7.45 billion, falling short of analyst estimates, which could raise concerns about its growth trajectory.
  • Despite recent positive movements, the stock has shown volatility, with a beta of 0.22, indicating it may not respond strongly to market changes, which could limit potential gains.
  • Some institutional investors, like Northern Trust Corp, have reduced their stakes, which may signal a lack of confidence in the company's short-term performance.
  • The company has a high price-to-earnings (P/E) ratio of around 51.52, suggesting that the stock may be overvalued relative to its earnings, which could deter value-focused investors.

TAK Forecast - Frequently Asked Questions

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Takeda Pharmaceutical in the last year. There is currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TAK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TAK, but not buy additional shares or sell existing shares.

According to analysts, Takeda Pharmaceutical's stock has a predicted downside of -100.00% based on their 12-month stock forecasts.

Over the previous 90 days, Takeda Pharmaceutical's stock had 1 downgrade by analysts.

Takeda Pharmaceutical has been rated by research analysts at Zacks Research in the past 90 days.

Analysts like Takeda Pharmaceutical less than other "medical" companies. The consensus rating for Takeda Pharmaceutical is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how TAK compares to other companies.

Related Companies
Today's Ratings
Top-Rated Stocks
More Ratings Tools

This page (NYSE:TAK) was last updated on 9/14/2025 by MarketBeat.com Staff
From Our Partners
Trump set to Boost Social Security Checks by 400%?
If you're collecting or planning to collect social security... You should see this presentation about Presi...
InvestorPlace | Sponsoredtc pixel
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...
American Alternative | Sponsoredtc pixel
Elon’s Secret Social Security Bombshell
To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...
Banyan Hill Publishing | Sponsoredtc pixel
What President Trump’s Executive Order 14154 means for your money
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...
Stansberry Research | Sponsoredtc pixel
Apple’s falling behind
Apple just posted record-breaking results, yet its stock barely moved — because in today’s market, investors o...
Porter & Company | Sponsoredtc pixel
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsoredtc pixel
$15 Fund: Turn Gold Boom into Real Income
If you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...
Investors Alley | Sponsoredtc pixel
The $17B signal no one expected…
After SpaceX struck a $17 billion deal with EchoStar for a block of radio frequencies, tech analyst Jeff Brown...
Brownstone Research | Sponsoredtc pixel